Synthio Labs has secured $5 million in seed funding to redefine how life sciences companies connect with doctors and patients, backed by Elevation Capital, 1984 Ventures, Peak XV Partners, Y Combinator, and several global healthcare leaders. Elevation Capital’s Krishna Mehra said Synthio is building “the next big customer engagement infrastructure for pharma,” powered by clinical-grade voice AI capable of delivering trusted, compliant responses around the clock. He added that the company’s vision represents “a reinvention of a trillion-dollar global commercial footprint.”
Founded by Supreet Deshpande, Sahitya Sridhar, and Rajashekar Vasantha, Synthio aims to modernise how the healthcare ecosystem communicates. “The future of healthcare will depend on how we reach and support every clinician and patient who relies on breakthrough medicines,” Deshpande said. The company’s AI Operating System—featuring Jarvis, Ather, and Simulation Studio—helps pharmaceutical teams automate conversations, collect structured insights, and deliver human-level engagement at scale. Early deployments have reached thousands of patients within hours, showcasing the potential for rapid, personalised support.
Real-world validation is accelerating Synthio’s growth. Soteri Skin CEO Rafal Pielak noted that Synthio’s voice AI managed “five thousand patient calls in just two days,” fully automating onboarding and assistance. With teams spread across India and the U.S. and experience from McKinsey, ZS, Amazon, and Audible, the startup now plans to expand its engineering and product capabilities. Synthio aims to scale its platform across the U.S. and Europe, positioning AI-driven engagement as the new global standard for healthcare communication.
